Together, these results indicate that inhibition of IDO1, mainly expressed in tumor endothelial cells, reduced expression of immunosuppressive molecules associated with T-cell exhaustion during agonistic CD40 mAb therapy. This evidence concerns the gene CD40 and neoplasm.